Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug

 
• By Brenda Sandburg
  
startup on track
Vistagen believes it is on track to begin a pivotal Phase III trial for its lead drug candidate • Source: Shutterstock

More from Clinical Trials

More from R&D